STOCK TITAN
  1. Home
  2. Sec-filings
  3. CMMB
  4. [Form 3] Chemomab Therapeutics Ltd. Initial Statement of Beneficial Ownership

Chemomab (CMMB) CFO details ADS, option and RSU holdings in Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. Chief Financial Officer Fatal Sigal filed an initial ownership report showing current holdings in American Depositary Shares (ADSs), stock options, and restricted share units. The filing lists three option grants over ADSs with exercise prices of $39.31, $8.44, and $6.80 per ADS, expiring between November 2031 and June 2033, along with multiple ADS and RSU positions that vest in stages through 2029.

Positive

  • None.

Negative

  • None.
Insider Fatal Sigal
Role Chief Financial Officer
Type Security Shares Price Value
holding Stock option (right to buy American Depositary Shares) -- -- --
holding Stock option (right to buy American Depositary Shares) -- -- --
holding Stock option (right to buy American Depositary Shares) -- -- --
holding American Depositary Shares -- -- --
holding American Depositary Shares -- -- --
holding American Depositary Shares -- -- --
Holdings After Transaction: Stock option (right to buy American Depositary Shares) — 8,900 shares (Direct); American Depositary Shares — 9,728 shares (Direct)
Footnotes (1)
  1. The American Depositary Shares reported in this row consist of restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on October 1, 2024 and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028. The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on April 10, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029. The options reported in this row were granted to the Reporting Person by the Issuer on November 11, 2021, and are fully vested and exercisable as of the date of this report. The options reported in this row were granted to the Reporting Person by the Issuer on November 8, 2022, and vest and become exercisable according to following schedule: 25% on November 8, 2023, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on November 8, 2026. The options reported in this row were granted to the Reporting Person by the Issuer on June 14, 2023, and vest and become exercisable according to following schedule: 25% on June 14, 2024, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on June 15, 2027.
Option exercise price $39.31 per ADS Stock option over American Depositary Shares expiring November 11, 2031
Option exercise price $8.44 per ADS Stock option over American Depositary Shares expiring November 8, 2032
Option exercise price $6.80 per ADS Stock option over American Depositary Shares expiring June 14, 2033
Underlying option shares 8,900 ADSs Underlying American Depositary Shares for $39.31 options
Underlying option shares 7,350 ADSs Underlying American Depositary Shares for $8.44 options
Underlying option shares 25,715 ADSs Underlying American Depositary Shares for $6.80 options
Direct ADS holding example 9,728 ADSs American Depositary Shares shown as held directly
RSU full vesting date October 1, 2028 RSUs granted October 1, 2024 fully exercisable by this date
American Depositary Shares financial
"The American Depositary Shares reported in this row consist of restricted share units"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
restricted share units ("RSUs") financial
"consist of restricted share units ("RSUs") that were granted to the Reporting Person"
stock option financial
"Stock option (right to buy American Depositary Shares)"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest and become exercisable financial
"vest and become exercisable according to following schedule: 25% on October 1, 2025"
quarterly installments of 6.25% financial
"thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Fatal Sigal
(Last)(First)(Middle)
C/O CHEMOMAB THERAPEUTICS LTD.
10 HABARZEL ST., BUILDING C, 10TH FLOOR
(Street)
TEL AVIV6158101
(City)(State)(Zip)
ISRAEL
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
Chemomab Therapeutics Ltd. [ CMMB ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
American Depositary Shares9,728D
American Depositary Shares(1)15,222D
American Depositary Shares(2)12,500D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy American Depositary Shares) (3)11/11/2031American Depositary Shares8,900$39.31D
Stock option (right to buy American Depositary Shares) (4)11/08/2032American Depositary Shares7,350$8.44D
Stock option (right to buy American Depositary Shares) (5)06/14/2033American Depositary Shares25,715$6.8D
Explanation of Responses:
1. The American Depositary Shares reported in this row consist of restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on October 1, 2024 and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028.
2. The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on April 10, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029.
3. The options reported in this row were granted to the Reporting Person by the Issuer on November 11, 2021, and are fully vested and exercisable as of the date of this report.
4. The options reported in this row were granted to the Reporting Person by the Issuer on November 8, 2022, and vest and become exercisable according to following schedule: 25% on November 8, 2023, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on November 8, 2026.
5. The options reported in this row were granted to the Reporting Person by the Issuer on June 14, 2023, and vest and become exercisable according to following schedule: 25% on June 14, 2024, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on June 15, 2027.
Remarks:
This Form 3 has been filed after March 18, 2026 but prior to April 20, 2026 in reliance on the temporary relief made available to the directors and officers of certain foreign private issuers by the Staff of the Securities and Exchange Commission in its no-action letter dated March 13, 2026.
/s/ Sigal Fattal04/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the Chemomab (CMMB) Form 3 filing by Fatal Sigal show?

The Form 3 shows Fatal Sigal’s initial holdings in Chemomab securities as Chief Financial Officer, including American Depositary Shares, stock options, and restricted share units. It details option exercise prices, expiration dates, and RSU vesting schedules that extend through 2029, without reporting any new trades.

How many Chemomab (CMMB) ADSs are covered by Fatal Sigal’s stock options?

The filing lists stock options over 8,900, 7,350, and 25,715 American Depositary Shares. These options have exercise prices of $39.31, $8.44, and $6.80 per ADS and expire between November 2031 and June 2033, reflecting existing equity-based compensation arrangements.

What are the exercise prices and expirations of Fatal Sigal’s Chemomab stock options?

Sigal holds options with exercise prices of $39.31, $8.44, and $6.80 per American Depositary Share. According to the filing, these options expire on November 11, 2031, November 8, 2032, and June 14, 2033, respectively, and represent long-dated equity incentives.

What RSU vesting schedules are disclosed for Chemomab (CMMB) CFO Fatal Sigal?

The filing describes RSUs granted on October 1, 2024 and April 10, 2025. Each grant vests 25% on the one-year anniversary, then in 12 equal quarterly installments of 6.25%, so the October 2024 RSUs fully vest by October 1, 2028 and the April 2025 RSUs by April 10, 2029.

Does the Chemomab (CMMB) Form 3 indicate any recent insider buying or selling?

The Form 3 is an initial ownership statement and lists holdings and award terms rather than new transactions. All entries are categorized as holdings with unknown transaction codes, so it does not indicate recent open-market purchases or sales by Fatal Sigal.

What direct ADS holdings does Fatal Sigal report in Chemomab (CMMB)?

The filing lists several direct positions in American Depositary Shares, including rows showing 9,728, 15,222, and 12,500 ADSs following the reported holdings. Some of these ADS positions are tied to RSU grants that vest over multiple years according to the disclosed schedules.